Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period

Andrea M. Haqq, Wendy K. Chung, Hélène Dollfus, Robert Haws, Gabriel Ángel Martos‐Moreno, Christine Poitou, Jack A. Yanovski, Robert S. Mittleman, Guojun Yuan, Elizabeth Forsythe, Karine Clément, Jesús Argente